Trial Profile
A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Pemetrexed (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 02 Feb 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 02 Feb 2023 Planned primary completion date changed from 31 Jan 2023 to 31 Jan 2025.
- 19 Aug 2022 Status changed from recruiting to active, no longer recruiting.